Plain-English translation of NCT06485843 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a treatment called , which uses adult stem cells injected directly into the knee joint, for people with moderate to severe osteoarthritis of the knee. Researchers want to find out if this treatment is safe and well-tolerated, and whether it can reduce pain and improve how well the knee works. The trial will enroll about 400 participants.
Knee osteoarthritis is a common condition that causes pain and disability, especially in older adults, and current treatment options may not work well for everyone. This study aims to see if stem cell therapy offers a new and effective way to help people with moderate to severe knee arthritis.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the stem cell treatment directly into your knee joint. Throughout the study, you'll attend regular clinic visits for check-ups and monitoring to see how you're responding and to report any side effects or changes in your knee pain and function. The study is open-label, meaning both you and the research team will know you are receiving the treatment, and you'll need to follow the visit schedule and avoid certain restricted arthritis medications during the study period.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Ageless Biotech, Inc.
Enrollment target
~400 participants
Started
May 2025
Primary completion
March 2028
Age range
35 Years – 75 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vince Liguori
Ageless Biotech, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.